2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
申请人:AGIOS PHARMACEUTICALS, INC.
公开号:US10376510B2
公开(公告)日:2019-08-13
Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
提供了式 (I) 的化合物,其中:环 A 和环 B 各自独立地为任选取代的 5-6 位单环芳基或杂芳基;X、Y 和 W 中的一个为 CH,另外两个为 N;Z 为 H 或 -C(R1)(R2)(R3)。这些化合物是异柠檬酸脱醛酶 2(IDH2)突变体的抑制剂,可用于治疗癌症。